Moreover, though it is noteworthy that a therapy to delay onset of clinically apparent disease was recently approved for clinical use19, there are still no DMTs that preserve endogenous insulin secretion in individuals recently diagnosed with T1D and only one in the prevention setting. Here, INS is linked to type 1 diabetes mellitus.